Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market

MEA Ovarian Cancer Diagnostics & Therapeutics Market Analysis

The Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market size is estimated at USD 263.92 million in 2025, and is expected to reach USD 386.00 million by 2030, at a CAGR of 7.9% during the forecast period (2025-2030).

The COVID-19 pandemic impacted the growth of the Middle East and African cancer diagnostics and therapeutics market. For instance, an article published by the National Centre for Biotechnology Information (NCBI) in May 2022 reported that the COVID-19 pandemic has disrupted cancer care to a certain degree in Saudi Arabia. The article also reported that women with ovarian cancer had disruptions in their treatment plans during COVID-19 due unavailability of proper ovarian cancer diagnostics in the country, as a result of the growth of the studied market being hampered due to COVID-19. In the current scenario, it is expected that with the decrease in COVID-19 cases and ease in restriction, diagnostics services may resume in the country. Thus, the studied market is expected to witness growth over the forecast period.

The major factors that are responsible for the growth of the market include the growing burden of ovarian cancer and the use of combination therapies for the treatment of ovarian cancer. An article published by the American Society of Clinical Oncology Journal in March 2022 reported that, of 463,675 new cancer cases estimated to be in Arab countries, 5.2% of the total cancers accounted for ovarian cancers. Similarly, another article published by NCBI in April 2022 reported that the prevalence of ovarian cancer in South Africa was 4.9% in the year 2020-2021. Thus, the high prevalence of ovarian cancer is increasing the demand for ovarian cancer diagnostics and therapeutics in the MENA region, thereby driving the growth of the studied market.

Also, another article published by the Saudi Pharmaceutical Journal in January 2023 reported that in Saudi Arabia, according to the National Cancer Registry, ovarian cancer is the seventh most common cancer, representing 3.3 % of the total cancers affecting women. The article also quoted that ovarian cancer is the 10th most lethal cancer among several other cancers as per the latest data from the International Agency for Research on Cancer. Thus, such instances are driving the demand for diagnostics and therapeutics for the studied market.

Furthermore, technological developments and new product launches are expected to drive the growth of the studied market. For instance, in February 2023, United Imaging, a global innovator in cutting-edge medical imaging and radiotherapy equipment, attended Arab Health 2023 as a Platinum partner in Dubai, UAE, with a broad range of state-of-the-art medical imaging devices, including HD TOF PET/MR uPMR 790; cardiac CT, the ultra-fast high-resolution digital PET/CT uMI 780; the newly launched uAiFI-powered 1.5T Wide Bore MRI System with "3T-like" performance, the uMR 680; and the most compact mobile DR system, uDR 380i Pro. Thus,

Thus, the growing burden of ovarian cancer and the new product launches are driving the growth of the studied market. However, a lack of awareness in emerging and low-income economies is slowing down the growth of the studied market.

MEA Ovarian Cancer Diagnostics & Therapeutics Market Trends

CT Scan Segment is Expected to Show Better Growth in the Forecast Period.

Computed Tomography (CT) is an imaging procedure that uses special X-ray equipment to create detailed pictures, or scans, of areas inside the body. It is also called computerized tomography and computerized axial tomography (CAT). This equipment does not show small ovarian tumors well, but they can see larger tumors and may be able to see if the tumor is growing into nearby structures. It can also find enlarged lymph nodes, signs of cancer spreading to the liver or other organs, or signs that an ovarian tumor is affecting the kidneys or bladder. Furthermore, the rising burden of ovarian cancer and technological advancements are expected to fuel market growth over the forecast period.

The high number of ovarian cancers in MENA countries is expected to contribute to the studied segment's growth. For instance, an article published by the Egyptian Journal of Medical Human Genetics in August 2022 reported that the incidence of ovarian cancer is expected to rise steadily by 260% of its present reported cases. Upper Egypt (6.1%) had the highest incidence, 6.1%. Lower rates were found in middle and lower Egypt (3.8% and 3.9%, respectively). Thus, the high incidence of ovarian cancer is expected to increase the demand for CT scans for its diagnosis, thereby driving the studied segment's growth.

Further, the new product developments are expected to drive the growth of the studied segment. For instance, in February 2023, GE HealthCare launched the Smart CT solution in the UAE. This is designed to help healthcare systems care for more patients with greater efficiency and enhanced clarity with up to 50% increased patient throughput, up to 30% enhanced image quality, and 85% faster daily prep thanks to improved efficiencies with higher workflow speed.

Thus, the high incidence of ovarian cancer and new product launches are expected to drive the segment's growth over the forecast period.

South Africa is Expected to Witness High Growth Over the Forecast Period.

The increasing prevalence of ovarian cancer cases among the South African population is expected to play a vital role in the growth of the studied market in South Africa. For instance, the article published in Springer Journal in March 2022 mentioned that the most prevalent cancer in Egypt was ovarian cancer (3.4%) among all cancers. Such a high prevalence of ovarian cancer among the African population is expected to contribute to the growing demand for MRI owing to the effective diagnosis, thereby fueling segment growth.

Moreover, establishing various diagnostic facilities in the country is also expected to drive the market in the country. For instance, in October 2021, Integrated Diagnostics Holdings launched Al-Borg Scan’s third branch in Egypt. The branch is equipped with the latest state-of-the-art radiology available on the market and offers a full suite of radiology services. Thus, such technological advancements are providing better diagnostic options to the people in the country, thereby driving the market.

Thus, due to the factors above, such as the high incidence of chronic diseases, the rising geriatric population, and frequent developments in the country, it is expected to witness significant growth, which can drive the studied market over the forecast period.

MEA Ovarian Cancer Diagnostics & Therapeutics Industry Overview

The Middle East and African ovarian cancer diagnostics and therapeutics market is moderately competitive and comprised of a few companies operating locally and regionally. With the rising research and development, the companies working in this market segment are launching novel products, and more companies are expected to penetrate the market. Some of the companies operating in this market segment are AstraZeneca plc, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline Plc, Johnson and Johnson (Janssen Pharmaceuticals), Pfizer Inc. and Siemens Healthineers AG.

MEA Ovarian Cancer Diagnostics & Therapeutics Market Leaders

MEA Ovarian Cancer Diagnostics & Therapeutics Market News

• February 2023: San Francisco-based iSono Health partnered with Middle East-based Abdul Latif Jameel Health to become the exclusive distributor of iSono Health’s ATUSA scanner (AI-driven portable 3D breast ultrasound scanner) in UAE. This partnership is a significant milestone in making our ATUSA scanner accessible to millions more women across the UAE.
• September 2022: Accuracy Incorporated reported that the company was expanding its global footprint with the introduction of its CyberKnife platform in Africa, making it possible for more patients to obtain access to the extremely precise stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments the system delivers.